501362-93-2Relevant academic research and scientific papers
ARYLCYCLOAKYL-SUBSTITUTED ALKANOIC ACID DERIVATIVES USEFUL AS PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) LIGANDS FOR THE TREATMENT OF HYPERLIPIDEMIA AND DIABETES
-
, (2008/06/13)
The present invention comprises compounds and compositions for the treatment of metabolic disorders and more particularly, those insulin-related metabolic disorders of the blood such as hyperlipidemia, diabetes, insulin-resistence and the like comprising acetic acid derivatives with arylcycloalkyl-substituted alkanoic acid derivatives and their salts. Known as peroxisome proliferator-activated receptors (PPAR) agonists/antagonists, the invention relates to compounds of the formula I wherein the various substituent R-groups are more specifically defined herein.
N-(PHENYL-OXAZOL-4-YLMETHOXYMETHYL)-CYCLOHEXYL-SUCCINIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS WHICH ARE USED AS PPAR-LIGANDS (PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS) FOR THE TREATMENT OF HYPERLIPIDAEMIE AND DIABETES
-
Page/Page column 38, (2008/06/13)
The invention relates to aryl-cycloalkyl substituted alkanoic acid derivatives in addition to the physiologically compatible salts thereof and physiologically functional derivatives. The invention also relates to compounds of formula (I), wherein the radicals have the above-mentioned meaning, in addition to physiologically compatible salts thereof and method for the production thereof.The compounds are suitable, for example, for treating and/or preventing disorders of the fatty acid metabolism and disorders of glucose utilisation in addition to disorders, in which insulin resistance plays a part.
Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals
-
Page/Page column 25-26, (2008/06/13)
Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals The invention relates to arylcycloalkyl-substituted alkanoic acid derivatives and to their physiologically acceptable salts and physiologically functional derivatives. What is described are compounds of the formula I, 1 in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable, for example, for the treatment and/or prevention of disorders of the fatty acid metabolism and glucose utilization disorders and also disorders in which insulin resistance is involved.
Process for preparing the enantiomeric forms of cis-configured 1,3-cyclohexanediol derivatives
-
Page 11, (2010/02/08)
Process for preparing the enantiomeric forms of cis-configured 1,3-cyclohexanediol derivatives A process is described for preparing chiral, nonracemic, cis-configured 1,3-disubstituted cyclohexanols of the formula (I) where the radicals are as defined, by
